Jove
Visualize
お問い合わせ
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. 急性冠動脈症候群患者のpcsk-9阻害剤の有効性と安全性: 系統的レビューとネットワークメタ解析
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. 急性冠動脈症候群患者のpcsk-9阻害剤の有効性と安全性: 系統的レビューとネットワークメタ解析

関連する実験動画

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.2K

急性冠動脈症候群患者のPCSK-9阻害剤の有効性と安全性: 系統的レビューとネットワークメタ解析

Guoying Kao1, Chuan Chen1, Ying Zhang1

  • 1Department of Cardiovascular Medicine, Chongqing Emergency Medical Center, Chongqing University Central Hospital, No.1 Health Road, Yuzhong District, Chongqing, 400010, China.

BMC cardiovascular disorders
|August 23, 2025

PubMed で要約を見る

まとめ
この要約は機械生成です。

PCSK9阻害剤は,急性冠動脈症候群 (ACS) の患者において,LDL- Cを著しく低下させ,心血管疾患を減少させます. エボロキュマブとアリロキュマブは,二次予防における使用を支える,類似した全体的な効果を示しています.

科学分野:

  • 心臓病科
  • 薬理学について

背景:

  • 急性冠動脈症候群 (ACS) は心臓血管疾患による死亡の主な原因である.
  • 低密度の脂質タンパク質コレステロール (LDL- C) の上昇は,ACSの重要な可変リスク因子です.
  • スタチンを服用している多くのACS患者は,LDL- Cの目標値に達せず,PCSK9阻害剤のような追加の治療が必要になります.

研究 の 目的:

  • ACS患者におけるPCSK9阻害剤 (エボロキュマブおよびアリロキュマブ) の有効性と安全性を体系的に評価する.
  • LDL-Cの低下と主要な心血管不良事件 (MACE) への影響を評価する.

主な方法:

  • 主要なデータベース (PubMed,Embase,Cochrane Library,ClinicalTrials.gov,WHO ICTRP) で包括的な文献検索が行われました.
  • 適格なランダム化対照試験 (RCT) でLDL- CとMACEのアウトカムが報告されました.
  • 介入を比較するために直接的なメタ分析とネットワークメタ分析が行われました.

主要な成果:

  • 37, 934人の患者の9つのRCTを分析した.
  • PCSK9阻害剤は,LDL- C (MD: - 52. 7 mg/ dL) とMACE (OR: 0. 79) を著しく低下させた.
キーワード:
急性冠動脈症候群LDL-C についてマースネットワークメタ解析PCSK-9 について

さらに関連する動画

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.6K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K

関連する実験動画

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.2K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.6K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K

関連する概念動画

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

72
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
72
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

46
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
46
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

676
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
676
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー
  • エボロキュマブはLDL- Cの減少を強く示し,アリロキュマブはMACEの減少を強く示し,薬剤間には統計的に有意な差異はなかった.

    • 結論:

    • PCSK9阻害剤は,ACS患者の脂質プロフィールを効果的に改善し,心血管疾患のリスクを軽減します.
    • エボロキュマブとアリロキュマブは,二次予防における役割を支持し,比較可能な効果を提供します.
    • LDL-CとMACEに対する差異的な効果を探るにはさらなる研究が必要である.